BioVersys AG

BV100 Phase 2 results indicate safety, tolerability, and efficacy in VABP patients with CRAB. Strategic investments from GIBF and GSK support BV100 and alpibectir development, with Phase 3 trials planned for 2025. BV100 targets RNA-polymerase in Gram-negative bacteria, addressing high mortality CRAB infections.

BioVersys secures $6m investment from GIBF2 for BV100 development in China, targeting CRAB infections. Phase 1 study to start in 1H 2025, leading to global Phase 3 trial.